Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch
STONY BROOK, N.Y. & ROME–(BUSINESS WIRE)–Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (Evvivax), today…
